title: Hormone interference in metastatic breast cancer patients treated with medroxyprogesterone acetate at massive doses: preliminary results.
authors.forename: G
authors.initials: G
authors.lastname: Sala
authors.forename: E
authors.initials: E
authors.lastname: Castegnaro
authors.forename: G R
authors.initials: GR
authors.lastname: Lenaz
authors.forename: A
authors.initials: A
authors.lastname: Martoni
authors.forename: E
authors.initials: E
authors.lastname: Piana
authors.forename: F
authors.initials: F
authors.lastname: Pannuti
mesh_terms: D001695:Biology; D001943:Breast Neoplasms; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D004194:Disease; D004703:Endocrine System; D005193:Family Planning Services; D005640:Follicle Stimulating Hormone; D006728:Hormones; D007986:Luteinizing Hormone; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms; D010827:Physiology; D011388:Prolactin
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D006728:Hormones; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate
keywords: Biology; Breast Cancer; Cancer; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Diseases; Endocrine System; Family Planning; Follicle Stimulating Hormone; Hormones; Luteinizing Hormone; Medroxyprogesterone Acetate--administraction and dosage; Neoplasms; Physiology; Prolactin